“The billions announced today in public funding must come with ‘strings attached’: pharmaceutical companies must commit to comprehensive technology transfer to expand manufacturing capacity in the global South and the Biden administration must commit to exercising emergency powers and use of intellectual property flexibilities if the private sector does not cooperate. They already control the supply and the price, and this announcement solidifies their power to determine who has access to life-saving medicines and who doesn’t. “The Biden administration knows that a call for proposals from ‘experienced mRNA manufacturers’ can only be answered by the same companies that have refused to engage in any voluntary technology transfer and have actively campaigned against the intellectual property waiver proposed by South Africa and India at the World Trade Organization (WTO). For example, the administration under the DPA will expand the priority rating on the federal government's vaccine production contract with Pfizer to ensure the company has priority access to filling pumps and tangential flow filtration skid units, which are two critical components the company needs to manufacture its Covid-19 vaccine, Manning said. manufacturing, financing, distribution, and administration of a COVID-19 vaccine will require unprecedented government planning, action, and coordination at both the federal and state levels. Without that access to knowledge – knowledge developed through publicly funded research – their lives will always be an afterthought. 30, 2023, the administration plans to extend the national emergency to May 11, 2023, then end it on that date. “Countries in the poorest parts of the world have been demanding access to the know-how to make COVID-19 vaccines themselves, so they are not beholden to the whims of pharma. As announced by the Biden Administration on Jan. Asia Russell, Health GAP Executive Director, said: “This is a dire global health emergency, and instead of using their power to compel pharma companies to share know-how to build capacity and rapidly expand vaccine manufacturing around the world, the Biden administration is promising billions more in public funding to the most profitable, powerful companies in the world to increase manufacturing in the U.S. Asia Russell, Health GAP Executive Director, said: This is a dire global health emergency, and instead of using their power to compel pharma companies to share know-how to build capacity and rapidly expand vaccine manufacturing around the world, the Biden administration is promising billions more in public funding to the most profitable.
0 kommentar(er)
